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cells: an in vitro and in vivo study
Riccardo Marega,†a Linda Karmani,†b Lionel Flamant,†c Praveen Ganesh Nageswaran,a Vanessa Valembois,d
Bernard Masereel,e Olivier Feron,f Thierry Vander Borght,f Stephane Lucas,*d Carine Michiels,*c
Bernard Gallez*b and Davide Bonifazi*ag
Received 30th May 2012, Accepted 29th July 2012
DOI: 10.1039/c2jm33482hGold nanoparticles (5 nm) coated with plasma-polymerized allylamine were produced through
plasma vapor deposition and bioconjugated with a monoclonal antibody targeting the epidermal
growth factor receptor. The resulting nanoconjugates displayed an antibody loading of about 1.7 nmol
mg1 and efficiently target epidermal growth factor receptor overexpressing cell lines, as ascertained by
ELISA and Western blot assays. The in vitro targeting properties were also confirmed in vivo, where a
similar biodistribution profile of what was experienced for the unconjugated antibody was observed.
Thanks to the possibility of doping the gold nanoparticles with radionuclides during plasma vapor
deposition, the proposed functionalization strategy represents a very suitable platform for the in vivo
cancer targeting with nanosized multifunctional particles.Introduction
Among the different technological fields, gold nanostructures
such as particles,1 rods,2 nanoshells3 and nanocubes4 have thor-
oughly been investigated for biomedical purposes.5,6 In fact,
thanks to their tuneable size, shape and optical absorption
properties,5,7 along with good biocompatibility profiles,8 these
nanomaterials have been proposed as sensors,9 imaging10 and
drug-delivery platforms.11–13 Most of these applications requireaNamur Research College (NARC) and Department of Chemistry,
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This journal is ª The Royal Society of Chemistry 2012surface modification of Au nanostructures, which can be easily
done either through adsorption of (bio)molecules bearing thiol
or amino functional groups,14 or by polymer coating.15 In some
instances, the resulting nanomaterials showed improved water
dispersability/solubility properties, therefore the assessment of
the interaction of such functional nanostructures with living
systems is of paramount importance for both biological prop-
erties and safety evaluation.13 Both the assessment of bio-
distribution profiles and toxicity of naked or functionalized gold
nanostructures has become a field of intensive research,16 as
recently summarized in an excellent review by Khlebtsov and
Dykman.17 It is clear that the biodistribution profiles depend on
several factors, such as particle shape, size and surface coating
properties, each one affecting the resulting pharmacokinetic
profile.17 One of the major fields of research for application of
gold nanoparticles (AuNPs) is cancer treatment, where a selec-
tive accumulation of (multi)functional nanomaterials in the
tumor is desired. In this respect, several reports about nano-
particle surface modifications aimed at cancer targeting have
been reported in the last few years,18 among others, those
describing antibody-coupling represent a major interest.19,20 In
particular, antibodies (Abs) targeting the epidermal growth
factor receptor (EGFR),21 a membrane protein overexpressed in
several kinds of solid tumors, have been conjugated to AuNPs
and efficiently employed for imaging,19,22 photothermal treat-
ment23 and drug delivery.12,24 Additionally, it has been shown
that this ‘‘nanoconjugation’’ uniformly enhances the antibody-
induced EGFR endocytosis for several cancer cell lines.25Aiming
at maximizing the cancer uptake of such nanoconjugates, it is of
great importance to determine the biodistribution of antibody-
functionalized AuNPs (AuNPs-Ab) in murine modelsJ. Mater. Chem., 2012, 22, 21305–21312 | 21305
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View Onlinexenografted with human cancers. Thus, in the present work, we
took advantage of the amino functionalities exohedrally exposed
on relatively small sized (5 nm) polymer-coated AuNPs
(AuNPs-PPAA), synthesized through simultaneous plasma
vapor deposition of Au (core) and allylamine (which leads to a
plasma-polymerized-allylamine shell, PPAA),26 to covalently
immobilize via an amide linkage an EGFR-targeting Ab
Cetuximab,27 either in its native or 125I-radiolabelled form. The
resulting nanoconjugates have been thus tested to assess EGFR
targeting both in vitro and in vivo murine models. In vitro studies
showed the preferential binding of the nanoconjugate to EGFR
overexpressing cancer cells (A431), with very low aspecific
binding to EGFR non expressing cell lines (CHO and EAhy926),
and the blocking of the EGF-induced biochemical effects, as
assessed through Western blot analysis. In vivo results showed
that tumor uptake was not significantly different between free
and nanoconjugated Cetuximab, highlighting the preservation of
antibody recognition after the bioconjugation step.Fig. 2 Bright-field TEM images of AuNPs-PPAA on Cu grids: (a) as
produced and (b) after dispersion and diafiltration.Results and discussion
AuNPs-PPAA synthesis and bioconjugation with Ab and Ab-125I
Fig. 1 reports the synthetic pathway toward the preparation of
the bioconjugates between AuNPs-PPAA and purified Cetux-
imab, either in its native (Ab) or 125I-bearing form (Ab-125I),
generating AuNPs-PPAA-Ab and AuNPs-PPAA-Ab-125I,
respectively. The amino groups present in the polymeric shell of
AuNPs-PPAA were exploited for amide bond formation with
carboxyl groups located on Cetuximab, through carbodiimide
chemistry in buffer solution (Fig. 1a). By repeating the same
reaction, but without the use of the carbodiimide, a physical
mixture between AuNPs-PPAA and Cetuximab (AuNPs-PPAA/
Ab) was also prepared, as a reference compound (Fig. 1b).
To determine both morphology and size distribution of the
pristine nanostructures, AuNPs-PPAA were directly deposited
onto a TEM grid, revealing the presence of spherical objects with
an average size between 3 and 5 nm (Fig. 2a). After a diafiltration
step, necessary to remove excess, unbound PPAA left from PVD
cycles, spherical objects with diameters ranging from 3 to 15 nmFig. 1 Synthetic pathway for the synthesis of covalent AuNPs-PPAA-Ab (a)
green: PPAA coating. EDC ¼ 1-Ethyl-3(3-dimethylaminopropyl)carbodiimid
MES ¼ 2-(N-morpholino)ethanesulfonic acid.
21306 | J. Mater. Chem., 2012, 22, 21305–21312(mean¼ 4.83 1.69 nm, Fig. 2b), as a consequence of occasional
AuNPs agglomeration induced by the diafiltration process, were
clearly detected by TEM imaging. Diafiltered samples containingand physiadsorbed AuNPs-PPAA/Ab bioconjugates (b). Yellow: AuNPs,
e hydrochloride, NHSS ¼ N-Hydroxysulfosuccinimide sodium salt and
This journal is ª The Royal Society of Chemistry 2012
Fig. 3 Steady-state UV-Vis absorption spectra (——) and derivative
plots (dAbs/dl, ---) for Ab (a), AuNPs-PPAA (b), AuNPs-PPAA-Ab (c)
and AuNPs-PPAA/Ab (d).
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View OnlineAuNPs-PPAA-Ab, AuNPs-PPAA/Ab and reference starting
materials (i.e., AuNPs and Ab) were first analyzed by steady-
state UV-Vis spectroscopy (Fig. 3). The absorption spectrum of
Cetuximab shows the typical proteinic signature at 280 nm,
which belongs to the aromatic groups-bearing aminoacidic resi-
dues (i.e., phenylalanine, tyrosine, tryptophane and histidine),
and the peptidic feature at 220 nm, as also clearly displayed in the
dAbs/dl plot (Fig. 3a). On the other hand, the AuNPs-PPAA
absorption spectrum shows a surface plasmon absorption feature
at 530 nm, characteristic of small-sized AuNPs,7 and then a
steady absorbance increase towards the UV region, the latter
providing a characteristic peak centered at 208 nm in the dAbs/
dl plot (Fig. 3b). The dAbs/dl plot for samples containing
AuNPs-PPAA-Ab clearly shows a very good overlap with both
Cetuximab- and AuNPs-PPAA-centered signatures (Fig. 3c),
suggesting the simultaneous presence of the two moieties in the
bioconjugate and thus their covalent linkage.
In contrast, the dAbs/dl plot forAuNPs-PPAA/Ab only shows
the presence of the AuNPs-PPAA-centered features (Fig. 3d),
thus suggesting the efficient elimination of the non-covalently
linked Ab counterpart by discontinuous diafiltration.
To evaluate AuNPs-PPAA-Ab composition, thermogravi-
metric analysis under inert atmosphere was carried out (Fig. 4).
Under these conditions we expected to determine the pyrolyticFig. 4 Temperature-modulated (——) and derivative (dW/dT, ---) plots
of PPAA (a), AuNPs-PPAA (b), Ab (c) and AuNPs-PPAA-Ab (d),
recorded under N2 atmosphere.
This journal is ª The Royal Society of Chemistry 2012behaviour of the single components (Ab, PPAA and AuNPs)
constituting the bioconjugate AuNPs-PPAA-Ab. PPAA (Fig. 4a)
showed a main pyrolysis event in the range between 100 and
500 C, with a weight loss at 600 C of 30.53 wt%. AuNPs-PPAA
also showed a main pyrolysis occurring between 100 and 500 C,
with a weight loss at 600 C of 25.30 wt% (Fig. 4b). Since Au has
a high thermal stability (melting point at about 1060 C), we can
assume that the observed weight loss in AuNPs-PPAA is due to
the decomposition of the PPAA layer, allowing for composi-
tional estimation that gives 17.13 and 82.87 wt% for Au and
PPAA, respectively. By looking at Ab pyrolysis behaviour
(Fig. 4c), there is also a weight loss in the range between 100 and
500 C, with a clear maximum at about 300 C (Ab decompo-
sition thermal signature) and a related weight loss of 74.92 wt%
at 600 C.
AuNPs-PPAA-Ab conjugate plots (Fig. 4d) showed the
thermal signature of Ab decomposition at about 300 C, further
suggesting that the Ab coupling has occurred, and an increased
weight loss of 19.23 wt% compared to AuNPs-PPAA. Consid-
ering the residual weights observed for each compound at 600 C
(74.70 wt% for AuNPs-PPAA, 25.08 wt% for Ab) and the
additional weight loss after Ab immobilization, it is possible to
estimate the AuNPs-PPAA-Ab composition, which was 12.73
wt% for Au, 61.60 wt% for PPAA and 25.67 wt% for Ab (i.e.,
about 1.7 nmols of Ab per mg of material).
For the preparation of AuNPs-PPAA-Ab-125I a known radi-
olabeling procedure based on the Iodo-Gen method was
employed. The radioiodination yield for Ab was typically
70–80%, whereas the radiochemical purity immediately after
purification was greater than 99%. The resulting specific activity
was 7.4 kBq per mg Ab. The 125I-to-Ab ratio was about 0.014,
which means that roughly one out of seventy Ab carries one
125I atom. Samples were stored several days at 4 C and analyzed
for overall in vitro stability. The amount of free iodide in
purified Ab-125I remained below 2% even after 25 days at 4 C.Fig. 5 Electrophoresis gel profile of Ab-125I using SDS-PAGE 8% under
non-reducing conditions (a). The migration gel was scanned by a Bioscan
(b) and Phosphor Imager (c).
J. Mater. Chem., 2012, 22, 21305–21312 | 21307
Table 1 Measured radioactivity of aliquots (1 mL) of the conjugate at
various time intervals
t (h)
Measured activitya
(csec1)
Vtot
(mL)
Activity
(csec1)
t0 133 6.4 851
t1h 85.4 9.4 803
t24h 11.8 9.4 111
tFinal 24.7 5.0 125
a As the purification through diafiltration proceeded, a reduction of
radioactivity due to Ab-125I elimination occurred, until a steady value
of radioactivity (tFinal), consistent with partial Ab-
125I immobilization,
was assessed.
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View OnlineElectrophoresis of Ab-125I under non-reducing conditions
followed by autoradiography showed the 150 kDa Ab band and
a single peak of radioactivity (Fig. 5), which means that antibody
integrity remained preserved after the labelling procedure.
The conjugation reaction between AuNPs-PPAA and Ab-125I
was then performed under the same conditions as those
employed for unlabeled Cetuximab (Fig. 1a). Reaction progress
was monitored by measuring the total activity (csec1) of
aliquots sampled at periodic intervals (Table 1), which allowed
estimating an Ab-125I immobilization efficiency of about 20%.In vitro evaluation of EGFR targeting
At first, the relative binding affinity of AuNPs-PPAA-Ab toward
an EGFR overexpressing cell line has been determined by a cell
based ELISA study. To this aim, we have selected the A431 cell
line, since these cells express high amounts of EGFR (EGFR+).28
As a negative control, cells that do not express EGFR, Chinese
hamster ovary (CHO) cells, have been selected (EGFR).
Consequently, different concentrations of Ab and of AuNPs-
PPAA-Ab were tested both on EGFR+ and EGFR cells
(Fig. 6). As expected, Ab bound to EGFR+ cells in a concen-
tration-dependent manner, but not to EGFR- cells. Interestingly,
AuNPs-PPAA-Ab also bound to EGFR+ cells in a concentra-
tion-dependent way, suggesting the retention of the correct
Ab conformation for the epitope selection and interaction in
AuNPs-PPAA-Ab conjugates. A very slight unspecific binding ofFig. 6 Surface ELISA for Ab and AuNPs-PPAA-Ab on EGFR+ (A431)
and EGFR (CHO) cells. Different concentrations of Ab and of AuNPs-
PPAA-Ab were tested. The concentrations are expressed as mg of Ab per
mL. Results are presented as means  1 S.D (n ¼ 4).
21308 | J. Mater. Chem., 2012, 22, 21305–21312AuNPs-PPAA-Ab to EGFR cells was also observed. Similar
results were obtained for another EGFR cell line, EAhy926
endothelial cells (data not shown).
From the concentration-dependent ELISA outcomes, binding
affinity toward A431 cells was quantified. Half maximal effective
concentration (EC50) for Ab was estimated as 0.08 mg mL
1,
while the EC50 for AuNPs-PPAA-Ab was 0.19 mg mL
1. For the
same number of antibody molecules, the spatial distribution is
constrained around NPs for NP-coupled Ab in comparison to
free Ab so that not all the Abmolecules are available to recognize
the antigen that is distributed on the monolayer cell surface. This
could explain the apparent lower affinity of the Ab when coupled
to the NPs.
We then determined the capability to inhibit the EGF-induced
phosphorylation of EGFR (at tyrosine 1173) through phos-
phorylation assays and subsequent Western Blot Analysis.
Serum-starved cells (24 hours) were incubated with or without
Ab orAuNPs-PPAA-Ab for 7 minutes before being stimulated or
not with 10 ng mL1 EGF for 10 minutes. As expected EGF
stimulates EGFR phosphorylation, an effect that was inhibited if
cells were pre-incubated with Ab. Negative results were obtained
for both CHO and EAhy926 cells (EGFR). Fig. 7 shows that
such a competition was also observed in the presence of AuNPs-
PPAA-Ab. All these binding results shows that, although slightly
reduced compared to Cetuximab alone, the Ab affinity after
immobilization onto AuNPs-PPAA is qualitatively preserved.
In vivo assessment of EGFR targeting
EGFR targeting was studied in NMRI nude mice bearing A431
epidermoid carcinoma tumors. Comparative pharmacokineticFig. 7 Inhibition of EGF-induced phosphorylation of EGF receptors by
Ab or AuNPs-PPAA-Ab. A431 cells were incubated with Ab or Au-NPs-
PPAA-Ab for 7 min before being stimulated with 10 ng mL1 EGF for 10
min. Lysates were separated by electrophoresis and analyzed by Western
blotting using anti-EGFR or anti-phospho-EGF receptor (Tyr1173)
antibodies. Lamin B was used as the loading control. The ratio between
fluorescent intensity of the bands corresponding to phospho-EGFR and
to Lamin B was calculated for each lane.
This journal is ª The Royal Society of Chemistry 2012
Fig. 8 Biodistribution of 60 kBq of Ab-125I (A) or AuNPs-PPAA-Ab-125I (B) (13.5–16 mg) in nude mice bearing A431 tumors at 6, 24, 48 and 72 h after
injection. Columns, mean %ID per g normal tissue and tumor; bars, SEM (n ¼ 2–5).
Fig. 9 Tumor uptake of 60 kBq of Ab-125I or AuNPs-PPAA-Ab-125I
(13.5–16 mg) in nude mice bearing A431 tumors at 6, 24, 48 and 72 h after
injection. Columns, mean; bars, SEM (n ¼ 2–5).Do
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View Onlineassessment of both Ab-125I and AuNPs-PPAA-Ab-125I was eval-
uated by ex vivo biodistribution studies. The biodistribution data
are presented in Fig. 8. At each time post-injection, radioactivity
uptake levels in tumors were not significantly different betweenFig. 10 Tumor to blood ratios of 60 kBq of Ab-125I or AuNPs-PPAA-
Ab-125I (13.5–16 mg) in nude mice bearing A431 tumors at 6, 24, 48 and 72
h after injection. Columns mean; bars, SEM (n ¼ 2–5). *P < 0.05,
significant differences between Ab-125I and AuNPs-Ab-125I.
This journal is ª The Royal Society of Chemistry 2012the conjugates (Fig. 9). The highest tumor-to-blood ratio was
observed after 48 h for both groups and was respectively 2.38 
0.18 for Ab-125I and 1.10  0.42 for AuNPs-PPAA-Ab-125I.
Tumor-to-blood ratios were not significantly different between
the two groups except at 6 h post-injection (Fig. 10). This
difference can be explained by the blood pool activity that is
significantly different between the two groups at early time. The
most remarkable differences between both biodistribution
patterns were observed for uptake in lungs, spleen and liver. At
6 h pi., lungs and spleen uptake levels were 3.98  0.83 and
9.13  2.91 for Ab-125I, and 18.25  4.34 and 17.80  12.64 for
AuNPs-PPAA-Ab-125I, respectively. For liver, these values were
8.18  1.39 and 6.42  0.61 for Ab-125I and AuNPs-Ab-125I,
respectively. Uptake levels in kidneys, thyroid and skeletal
muscles were similar for both radioimmunoconjugates. The
reticuloendothelial system uptake is more important for AuNPs-
PPAA-Ab-125I than Ab-125I. This may explain the lower blood
activity at early times. For all normal tissues (liver, spleen,
kidneys, lungs and muscles), there is no specific uptake or
accumulation of AuNPs-PPAA-Ab-125I compared to the control
group. The radioactivity level decreased over time.
Very interestingly, despite the small decrease in binding
capacity of AuNPs-PPAA-Ab-125I to the EGFR target, tumor
uptake was not significantly different between the two groups.
Data thus indicate that coupling nanoparticles to Cetuximab
does not seem to affect the pharmacokinetic behaviour of the
antibody, and particularly the tumor uptake. Therefore, an
antibody conjugated to gold nanoparticles seems to maintain its
targeting activity towards EGFR over-expressed on tumor cells.
Nonetheless, the high thyroid uptake means an in vivo deiodi-
nation related to the degradation of Ab-125I, which induces a
rapid free iodine clearance and a low tumor contrast expressed as
a tumor-to-blood ratio.29 This chemical instability may lead to
errors in the estimation of the actual antibody tumor uptake.
Conclusions
Polymer-coated AuNPs have been efficiently produced by
plasma vapor deposition, through an automated batch wise
procedure, and subsequently covalently decorated with native or
radioiodinated Cetuximab through amide bond formation
reaction. The resulting bioconjugates selectively target EGFRJ. Mater. Chem., 2012, 22, 21305–21312 | 21309
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View Onlineoverexpressing cell lines, allowing for the in vitro binding of
cancer-like cells, as evaluated by ELISA and Western blot
analysis after phosphorylation studies. Although the occurrence
of the parasite deiodination of the radiolabeled Cetuximab, as
detected by high thyroid uptake, certainly affects (i.e., under-
estimating the observed value) the quantification of the accu-
mulation in the tumor tissues, the bioconjugates showed an
in vivo pharmacokinetic profile very similar to that of the
uncoupled Ab, thus supporting our idea that such nano-
structures are suitable scaffolds to be implemented for in vivo
treatments. In particular, the possibility of further doping the
AuNPs core with radioactive species during the PVD synthesis
opens the way toward the development of a new generation of
radioactive bioconjugates possibly displaying a theranostic
activity.
Experimental part
Materials
All chemicals were purchased from commercial sources and used
without further purification. 1-Ethyl-3-(dimethylaminopropyl)-
3-carbodiimide hydrochloride (EDC$HCl), N-hydroxy-sulpho-
succinimide sodium salt (NHSS) and 2-(N-morpholino)ethane-
sulphonic acid hydrate (MES) were obtained fromSigma-Aldrich
and used without further purification. Allylamine was obtained
fromSigma-Aldrich.Waterwas purified using aMilliporeMilli-Q
water production system. Commercially available Cetuximab
formulation (Erbitux 2 or 5 mg mL1, Merck & Co.) was
purified by discontinuous diafiltration in centrifugal concentra-
tors with a molecular weight cut-off (MWCO) of 10 000 g mol1
(Sartorius Vivaspin) and the purified antibody was isolated by
freeze-drying (Ab). Iodo-Gen kit was obtained from Pierce
Thermo scientific. 125I was purchased fromBestMedical Belgium
and radiolabeled antibodies were purified on a Sephadex G-25
column (GE Healthcare Europe).
Characterizations
Transmission electron microscopy (TEM) images were acquired
with a Philips Tecnai 10 transmission electron microscope
(TEM) operating at 80 keV and in bright-field mode. Samples for
TEM analysis were obtained by depositing onto carbon-coated
Cu grids directly during PVD process (Fig. 2a) or by using
suitable solutions of AuNPs-PPAA in H2O (Fig 2b). All the
thermogravimetric analyses were performed with a TGA Q500
instrument manufactured by TA instruments (Italy), under a N2
flow of 60 mL min1 and with the following method: equilibra-
tion from room temperature to 100 C, isothermal heating at
100 C for 20 min, then ramp from 100 C to 1000 C (heating
rate of 10 C min1). UV-Vis spectra were recorded on a Cary
5000 Spectrophotometer (Varian), using 1 cm path quartz or
optical glass cuvettes. Quality controls of radiolabeled antibodies
were performed by paper chromatography, Bioscan analysis
(Bioscan system 200 imaging scanner), SDS-PAGE electropho-
resis and by gel scanning through a Phosphor Imager (Fujifilm
FLA-5100). The amount of radioactivity in tumors, blood and
organs (liver, spleen, kidneys, lung, skeletal muscles and thyroid)
was measured in a gamma well counter (1480 Wallac Wizard 30 0
automatic g-counter; Perkin Elmer, Inc.).21310 | J. Mater. Chem., 2012, 22, 21305–21312Synthesis of AuNPs-PPAA and antibody conjugation
Synthesis of gold nanoparticles coated with plasma-polymerized
allylamine (AuNPs-PPAA) by plasma vapor deposition (PVD)
was already reported.26 The resulting NaCl embedded nano-
particles were then dispersed in acetate buffer (pH ¼ 5) under 5
min of sonication and then purified from the PPAA and NaCl
excess by discontinuous diafiltration in centrifugal concentrators
with a molecular weight cut-off (MWCO) of 10 000 g mol1. Ab
(5 mg) was dissolved in 10 mL of 0.1 M MES buffer (190 mg in
10 mL H2O, pH ¼ 7), and then a solution of EDC$HCl (2 mg,
0.01 mmol) and NHSS (2 mg, 0.01 mmol) in 10 mL of 0.1 M
MES buffer was added. The resulting mixture was stirred at
25 C for 15 min, after that a solution of AuNPs-PPAA (0.65 mg
mL1, 8.0 mL, 5.2 mg) in H2O was added. The reaction was
stirred at 25 C for 16 hours, after which it was purified by
discontinuous diafiltration against H2O in centrifugal concen-
trators with MWCO of 300 000 g mol1. Purification was
completed when the electrical conductivity of the filtrate was
almost equal to that of H2O. AuNPs-PPAA-Ab were isolated
through freeze-drying, affording a pinkish red powder (6.5 mg).Radioiodination of Cetuximab
Ab radioiodination with 125I was done using the Iodo-Gen
method as described in instructions of use by Pierce. In brief, a
mixture of sodium iodide (3700 MBq mL1) and Cetuximab
(20 mg mL1) dissolved in 0.01 M sodium phosphate buffered
saline (NaCl 0.14 M, pH 7.4) was added to an Iodo-Gen-coated
reaction vial (50 mg iodogen coating the inner surface of a 100 mL
vial) and reacted for 5 min at room temperature with stirring
every 30 seconds. Protein-bound iodine was separated from free
iodide by passing over a Sephadex G-25 column equilibrated
with PBS 0.01 M pH 7.4. Quality control of radiolabeled Ab
(Ab-125I) was performed by using paper chromatography (eluent:
MeOH–H2O, 70 : 30, v/v) followed by Bioscan analysis to
determine the radiochemical yield and purity. In addition,
Ab-125I integrity was checked by SDS-PAGE (8%, under non-
reducing conditions) and analyzed by a Bioscan and Phosphor
Imager.Synthesis of AuNPs-PPAA-Ab-125I
2 mg of Ab-125I were redissolved in 5 mL of 0.1 M MES buffer
and treated with a solution of EDC$HCl (1 mg, 0.005 mmol) and
NHSS (1 mg, 0.005 mmol) in 5 mL of 0.1 M MES buffer. The
mixture was stirred for 15 min at 25 C, after which a solution of
AuNPs-PPAA (0.65 mg mL1, 2.0 mL, 1.30 mg) in H2O was
added. The reaction was stirred at 25 C for a period of 16 hours
after which it was purified by diafiltration using a membrane
filter of molecular weight cut-off 300 000 g mol1. The purifi-
cation was completed when the electrical conductivity of the
filtrate was almost equal to that of H2O. The retentate was finally
redissolved in 3.0 mL of deionized H2O by sonication affording a
H2O solution of AuNPs-PPAA-Ab-
125I.Cell culture
Human epithelial carcinoma cells A431 and Chinese hamster
ovary cells CHO were maintained in culture in 75 cm2This journal is ª The Royal Society of Chemistry 2012
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View Onlinepolystyrene flasks (Corning) with respectively 15 mL of Dul-
becco’s modified Eagle’s medium (DMEM) or Roswell Park
Memorial Institute medium (RPMI 1640, Invitrogen), contain-
ing 10% of fetal calf serum (Invitrogen) and incubated under an
atmosphere containing 5% CO2.Surface ELISA
A431 or CHO cells (105 per well) were grown in 96 well plates
(Costar) 24 hours prior to the ELISA test. Cells were rinsed once
with PBS and then fixed 10 min with PBS containing 4% para-
formaldehyde. After one wash with PBS, wells were blocked with
5% of non-fat dry milk in PBS for 1 hour at room temperature.
Cells were rinsed one time with PBS and one time with BSA 1%
in PBS for 5 min. Ab orAuNPs-PPAA-Abwere added to the cells
at various concentrations for 1 hour at room temperature. Plates
were washed three times with PBS–BSA, and a mouse mono-
clonal anti-human IgG–biotin antibody (Sigma) diluted in PBS–
BSA at 1 mg mL1 was added for 1 hour at room temperature.
Cells were washed three times and incubated with streptavidin-
alkaline phosphatase (Sigma) for 30 min at room temperature.
After three washing steps with PBS–BSA and one with PBS,
alkaline phosphatase activity was revealed with 1 mg mL1
p-nitrophenylphosphate in 0.1 M diethanolamine pH 10.3 con-
taining 1.5 mM levamisole hydrochloride. The reaction was
stopped with NaOH 2 N and the surface expression was quan-
tified spectrophotometrically, reading the optical density
(405 nm) 45 min after addition of the substrate.Phosphorylation studies
A431 cells were grown to 90% confluence in complete medium in
T75 flasks, and they were starved in DMEM with 0.5% BSA
(Sigma) for 24 hours prior to stimulation. Cells were incubated
for 7 min with Ab or AuNPs-PPAA-Ab and then stimulated with
10 ng mL1 EGF (R&D Systems) for 10 min at 37 C. Following
stimulation, cells were washed with ice-cold PBS containing
1 mM sodium orthovanadate. Cells were lysed with a lysis buffer
(Tris 20 mM pH 7.5, NaCl 150 mM, EDTA 1mM, EGTA 1mM,
sodium deoxycholate 1%, Nonidet P40 1%, glycerol 10%) con-
taining a protease inhibitor mixture («Complete» from Roche
Molecular Biochemicals, 1 tablet in 2 mL H2O, added at a 1 : 25
dilution) and phosphatase inhibitors (NaVO3 25 mM, PNPP
250 mM, a-glycerophosphate 250 mM and NaF 125 mM, at a
1 : 25 dilution). Protein concentration in cell lysates was evalu-
ated by Bradford protein assay (Bio-rad) and 15 mg proteins were
separated by electrophoresis on a 3–8% Tris–acetate gel
(NuPage, Invitrogen). After semi-dry transfer onto a low IR
background PVDF (polyvinylidene fluoride) membrane (Milli-
pore) for 2 h at 1 mA cm2, the membrane was left for 2 h in Licor
blocking agent 2 diluted in PBS before incubation during 2 h
with the primary antibody diluted in Odyssey blocking buffer
(Licor) containing 0.1% Tween 20 (Sigma). The membrane was
washed 4  5 min with PBS-Tween 0.1%, incubated 1 h with
infrared dye specific secondary antibodies (Licor) diluted in
Odyssey + Tween 0.1% and washed 4  5 min with PBS-Tween
0.1% and 2  5 min with PBS before protein detection using the
Odyssey Infrared Imaging System (Licor). Fluorescence Western
blot analysis by infrared technology (Licor) allows theThis journal is ª The Royal Society of Chemistry 2012quantification of the fluorescent intensity of the bands corre-
sponding to the protein of interest. Western blotting analysis was
performed by infrared fluorescence with rabbit anti-phospho-
EGF receptor (Tyr1173) monoclonal antibody (# 4407 Cell
Signaling) used at 1/1000 dilution or rabbit anti-EGF receptor
monoclonal antibody (# 4267 Cell Signaling) used at 1/5000
dilution. Goat anti-lamin B antibody (SC-6212 Santa Cruz) (final
dilution 1/2000) was used for normalization. Rabbit or goat IgG
infrared dye-linked antibody (Licor) was used at 1/10 000 dilu-
tion as a secondary antibody.Comparative biodistribution studies in mice
NMRI nude mice (athymic nu/nu, 29–36 g, Janvier, France) were
5–8 weeks old at the time of the experiments. The human
epidermoid carcinoma cell line A431 (10  106) was injected
subcutaneously into the flank of each mouse. Biodistribution
studies were performed when tumors reached a size of approxi-
mately 7.5–8.5 mm. All animal experiments were approved by
the local ethics committee for animal research in compliance with
the principles of laboratory animal care. Two groups of mice
were injected i.v. into the lateral tail vein with either a mixture of
74 kBq Ab-125I (control group) or with AuNPs-PPAA-Ab-125I
(total of 13.5 to 16 mg of Ab per mouse). Typically, groups of
2–5 mice per time point (6, 24, 48 and 72 h after injection) were
anesthetized, weighed, killed by cervical dislocation and
dissected. Radioactivity uptake was expressed as the percentage
of injected dose per gram of tissue (%ID g1) and as tumor-to-
blood ratios. The results were expressed as the mean  SEM.
Data calculations were performed with Prism software (Graph-
Pad Software Inc.). The differences in tissue uptake between the
two groups were considered significant if the P values from
unpaired t tests were less than 0.05.Acknowledgements
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